BELATACEPT IN RENAL TRANSPLANTATION
https://doi.org/10.15825/1995-1191-2013-1-96-105
Abstract
Belatacept is a novel immunosuppressive agent that inhibits T-cell activation by blocking CD28 signaling pa- thway. It was developed based on abatacept (CTLA-4Ig), the first recombinant immunoglobulin fusion protein which contains extracellular part of CTLA-4 molecule and Fc domain of IgG. First clinical trials have shown the comparable patient and graft survival in group of kidney recipients with belatacept-based maintenance im- munosuppressive therapy versus Cyclosporin A-based therapy. Advantages observed with belatacept include superior glomerular filtration rate and improved cardiovascular risk profile. Belatacept is a potential option for maintenance immunosuppressive therapy without calcineurin inhibitors. Concerns associated with belatacept use are higher rates of acute cellular rejection episodes and post-transplant lymphoproliferative disorder cases.
About the Authors
A. I. Sushkov
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
Y. G. Moysyuk
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
I.M. Sechenov First Moscow State Medical University, Department of Transplantology and Artificial Organs, Moscow
References
1. Мойсюк Я.Г. и соавт. Иммуносупрессия при транс- плантации почки // Иммуносупрессия при транс- плантации солидных органов / Под ред. С.В. Готье. М.: Триада, 2011. С. 46–113.
2. Abrams J.R. et al. Blockade of T lymphocyte costimu- lation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pa- thology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells // J. Exp. Med. 2000. Vol. 192 (5). P. 681–694.
3. Adams A.B. et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival // J. Immunol. 2005. Vol. 174 (1). P. 542–550.
4. Cardona K. et al. Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways // Nat. Med. 2006. Vol. 12 (3). P. 304–306.
5. Davis P.M., Nadler S. and Suchard S.J. Belatacept does not mediate complement-dependent cytotoxicity or an- tibody-dependent cellular cytotoxicity // Am. J. Trans- plant. 2008. Vol. 8.
6. Durrbach A., Grinyo J. and Vanrenterghem Y. Bela- tacept compared with cyclosporine in renal allograft recipients of extended criteria donor kidneys: 3-year outcomes from the phase III BENEFIT-EXT trial, in Annual Congress ERA EDTA. 2011: Prague, Czech Republic.
7. Durrbach A. et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended crite- ria donors (BENEFIT-EXT study) // Am. J. Transplant. 2010. Vol. 10 (3). P. 547–557.
8. Emamaullee J.A. et al. Belatacept and basiliximab di- minish human antiporcine xenoreactivity and synergize to inhibit alloimmunity // Transplantation. 2008. Vol. 85 (1). P. 118–124.
9. Ferguson R. et al. Immunosuppression with belatacept- based, corticosteroid-avoiding regimens in de novo kidney transplant recipients // Am. J. Transplant. 2011. Vol. 11 (1). P. 66–76.
10. Fife B.T., Bluestone J.A. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways // Immunol. Rev. 2008. Vol. 224. P. 166–182.
11. Gaston R.S. Chronic calcineurin inhibitor nephrotoxici- ty: reflections on an evolving paradigm // Clin. J. Am. Soc. Nephrol. 2009. Vol. 4 (12). P. 2029–2034.
12. Grinyo J. et al. An integrated safety profile analysis of belatacept in kidney transplant recipients // Transplanta- tion. 2010. Vol. 90 (12). P. 1521–1527.
13. Hess R.D. Routine Epstein–Barr virus diagnostics from the laboratory perspective: still challenging after 35 ye- ars // J. Clin. Microbiol. 2004. Vol. 42 (8). P. 3381–3387.
14. Kirk A.D. et al. Induction therapy with monoclonal anti- bodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates // Transplantation, 2001. Vol. 72 (3). P. 377–384.
15. Kremer J.M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion pro- tein CTLA4Ig // N. Engl. J. Med. 2003. Vol. 349 (20). P. 1907–1915.
16. Larsen C.P. et al. Rational development of LEA29Y (be- latacept), a high-affinity variant of CTLA4-Ig with po- tent immunosuppressive properties // Am. J. Transplant. 2005. Vol. 5 (3). P. 443–453.
17. Latek R. et al. Assessment of belatacept-mediated co- stimulation blockade through evaluation of CD80/86- receptor saturation // Transplantation. 2009. Vol. 87 (6). P. 926–933.
18. Levisetti M.G. et al. Immunosuppressive effects of hu- man CTLA4Ig in a non-human primate model of allo- geneic pancreatic islet transplantation // J. Immunol. 1997. Vol. 159 (11). P. 5187–5191.
19. Li X.C., Rothstein D.M., Sayegh M.H. Costimulatory pa- thways in transplantation: challenges and new develop- ments // Immunol. Rev. 2009. Vol. 229 (1). P. 271–293.
20. Linsley P.S. et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors // Immunity. 1994. Vol. 1 (9). P. 793–801.
21. Linsley P.S. et al. Immunosuppression in vivo by a so- luble form of the CTLA-4 T cell activation molecule // Science. 1992. Vol. 257 (5071). P. 792–795.
22. Meier-Kriesche H.U., Schold J.D., Kaplan B. Long- term renal allograft survival: have we made significant progress or is it time to rethink our analytic and thera- peutic strategies? // Am. J. Transplant. 2004. Vol. 4 (8). P. 1289–1295.
23. Nankivell B.J. et al. The natural history of chronic al- lograft nephropathy // N. Engl. J. Med. 2003. Vol. 349 (24). P. 2326–2333.
24. Rangel E.B. Belatacept in clinical and experimental transplantation – progress and promise // Drugs Today (Barc). 2010. Vol. 46 (4). P. 235–242.
25. Sakaguchi S. et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and trans- plantation tolerance // Immunol. Rev. 2001. Vol. 182. P. 18–32.
26. Tang, Q. et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells // J. Im- munol. 2003. Vol. 171 (7). P. 3348–3352.
27. Vanrenterghem Y. et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies) // Transplantation. 2011. Vol. 91 (9). P. 976–983.
28. Vierboom M.P. et al. Induction of allograft tolerance through costimulatory blockade: first selection of drugs in vitro // Transpl. Immunol. 2003. Vol. 11 (2). P. 215– 222.
29. Vincenti F. et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in
30. renal transplant recipients (BENEFIT study) // Am. J.
31. Transplant. 2010. Vol. 10 (3). P. 535–546.
32. Vincenti F., Larsen C., Alberu J. Three-year outcomes from benefit: a phase III study of belatacept vs. cyclospo- rine in kidney transplant recipients., in Annual Congress
33. ERA EDTA. 2011: Prague, Czech Republic.
34. Vincenti F. et al. Costimulation blockade with belatacept in renal transplantation // N. Engl. J. Med. 2005. Vol. 353
35. (8). P. 770–781.
Review
For citations:
Sushkov A.I., Moysyuk Y.G. BELATACEPT IN RENAL TRANSPLANTATION. Russian Journal of Transplantology and Artificial Organs. 2013;15(1):96-105. (In Russ.) https://doi.org/10.15825/1995-1191-2013-1-96-105
Views:
1318
Email this article 